Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Anne Christine H Ruwald, Bo Westergaard, Thomas Sehestedt, Sverre E Kjeldsen, Lars H Lindholm, Kristian Wachtell, Richard B Devereux, Hans Ibsen, Markku S Nieminen, Björn Dahlöf, Michael H Olsen

8 Citationer (Scopus)

Abstract

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study has previously demonstrated a beneficial effect of losartan compared to atenolol-based antihypertensive treatment in patients with essential hypertension and left-ventricular hypertrophy (LVH). However, patient age often influences the choice of antihypertensive drugs. Therefore, we investigated the influence of age on the effects of losartan versus atenolol-based antihypertensive treatment.
OriginalsprogEngelsk
TidsskriftJournal of Hypertension
Vol/bind30
Udgave nummer6
Sider (fra-til)1252-9
Antal sider8
ISSN0263-6352
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study'. Sammen danner de et unikt fingeraftryk.

Citationsformater